Alexander Ullrich von Gabain
Chairman at Eit Health eV
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Lingelbach | M | 60 |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 18 years |
| James Sulat | M | 73 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 19 years |
| Franck Grimaud | M | 58 | 11 years | |
| Anne-Marie Graffin | F | 63 | 11 years | |
| Laetitia Bachelot-Fontaine | F | - | 11 years | |
| Frédéric Jacotot | M | 60 | 7 years | |
| Jeroen van der Veer | M | 76 |
European Institute of Innovation & Technology
| 12 years |
| Christian Fernand Jourquin | M | 75 |
European Institute of Innovation & Technology
| 13 years |
| Ronald Li | M | - |
Karolinska Institutet
| 8 years |
| Jan-Philipp Beck | M | - |
Eit Health eV
 Eit Health eV Medical/Nursing ServicesHealth Services Eit Health eV is a network of health innovators supported by the EU. The private company is based in Munich, Germany, and has subsidiaries in Spain. The German company collaborates across borders to provide new solutions that can help European citizens live longer and healthier lives. The company connects all relevant healthcare players across European borders, including research, education, and business, to bring innovative healthcare solutions to the market. The CEO of the company is Jan-Philipp Beck. | - |
| Cem Baydar | M | - |
Eit Health eV
Eit Health eV Medical/Nursing ServicesHealth Services Eit Health eV is a network of health innovators supported by the EU. The private company is based in Munich, Germany, and has subsidiaries in Spain. The German company collaborates across borders to provide new solutions that can help European citizens live longer and healthier lives. The company connects all relevant healthcare players across European borders, including research, education, and business, to bring innovative healthcare solutions to the market. The CEO of the company is Jan-Philipp Beck. | 5 years |
| Saurabh Tak | M | - |
Eit Health eV
Eit Health eV Medical/Nursing ServicesHealth Services Eit Health eV is a network of health innovators supported by the EU. The private company is based in Munich, Germany, and has subsidiaries in Spain. The German company collaborates across borders to provide new solutions that can help European citizens live longer and healthier lives. The company connects all relevant healthcare players across European borders, including research, education, and business, to bring innovative healthcare solutions to the market. The CEO of the company is Jan-Philipp Beck. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Reinhard Kandera | M | 54 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 16 years |
| Michel Gréco | M | 80 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 13 years |
| Hans Lennart Rudolf Wigzell | M | 86 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 3 years |
| Thomas D. Szucs | M | 64 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 2 years |
| Johanna Willemina Pattenier | M | 64 | 3 years | |
| Nicolas Jean Michel Cormier | M | - |
European Institute of Innovation & Technology
| 6 years |
| Ralf Clemens | M | 71 | 3 years | |
| Sandra E. Poole | F | 60 | 3 years | |
| Michael Buschle | M | 64 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | - |
| Ernst-Günter Afting | M | 80 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 14 years |
| Gonzalo Artiach Castanon | M | - |
Karolinska Institutet
| 5 years |
| Mustapha Bakali | M | 62 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 6 years |
| Sharon Tetlow | F | 64 | 3 years | |
| Gregory Glenn | M | 70 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 2 years |
| Katherine Cohen | M | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 11 years |
| CARL KILANDER | M | - |
Karolinska Institutet
| 5 years |
| Viktor Elmsjö | M | - |
Karolinska Institutet
| 2 years |
| Jan Ulf Sigvar J. Johansson | M | 79 |
European Institute of Innovation & Technology
| 4 years |
| Manfred Tiefenbacher | M | - | - | |
| Wolfgang Bender | M | 70 | 3 years | |
| Louisa Shaw-Marotto | F | 56 | 4 years | |
| Maria Luisa Garaña Corces | F | 56 |
European Institute of Innovation & Technology
| 5 years |
| Frédéric Legros | M | 48 | - | |
| David Ebsworth | M | 69 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 8 years |
| Bali Muralidhar | M | 44 | 2 years | |
| Christoph Klade | M | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | - |
| Nina Waibel | F | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | - |
| David Lawrence | M | 61 | - | |
| Aaron Hirsh | M | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | - |
| Gábor Zoltán Bojár | M | 75 |
European Institute of Innovation & Technology
| 4 years |
| Anne-Sophie Herelle | F | 43 | - | |
| Gerald Strohmaier | M | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | - |
| Lena Charlotte Strömberg | F | 65 |
Karolinska Institutet
| 3 years |
| Roman Necina | M | 56 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 4 years |
| Gianfelice Mario Rocca | M | 76 |
European Institute of Innovation & Technology
| 4 years |
| Walter Schmidt | M | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | - |
| Werner Lanthaler | M | 56 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 9 years |
| Gerd Zettlmeissl | M | 68 |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | 10 years |
| Majid Mehtali | M | 63 | - | |
| Thomas Casdagli | M | 47 | 2 years | |
| Viktor Drvota | M | 59 |
Karolinska Institutet
| 13 years |
| Max Birnstiel | M | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| France | 22 | 40.74% |
| Austria | 21 | 38.89% |
| Hungary | 7 | 12.96% |
| Sweden | 6 | 11.11% |
| Germany | 3 | 5.56% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alexander Ullrich von Gabain
- Personal Network
